Press Releases

Biocartis Announces Publication of 2019 Annual Report

Biocartis Announces Co-commercialization of the SeptiCyte® RAPID Test on Idylla™ (CE IVD) and Provides Update on COVID 19 Impact

Biocartis Announces New Immuno-Oncology Project with Bristol-Myers Squibb Aimed at Registration of Idylla™ MSI test in China

Biocartis Enters into Master Collaboration Agreement with AstraZeneca and Initiates EGFR Liquid Biopsy Study

Nichirei Biosciences to Initiate Market Introduction of Idylla™ Platform in Japan

Five Idylla™ Studies to be Published at ‘Association for Molecular Pathology’ Annual Meeting (US)

Biocartis Launches Liquid Biopsy Idylla™ ctEGFR Mutation Assay

Five Idylla™ Performance Studies to be Presented at ‘European Society for Medical Oncology’ congress

Study on Performance Data of Idylla™ NRAS-BRAF Mutation Assay at 71st AACC Annual Scientific Meeting in Anaheim, CA (US)

Biocartis and Kite Sign Agreement for Development of Assays supporting Kite’s Therapies